Business
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform response to biologics and patient stratification Presentation selected for DDW ‘Poster of Distinction’ recognition CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announc
About this update from Seres Therapeutics, Inc.
[{"type":"image","alt":"Seres Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Seres Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":205,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c9212fd90ce8aaab0f99113fa1623d37"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AevgeV1boJs7rC.lO5CETw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE0OQ--/https://media.zenfs.com/en/globenewswire.com/c9212fd90ce8aaab0f99113fa1623d37","width":205,"height":85}},"lazy":false},{"type":"text","content":"Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform response to biologics and patient stratification","length":265,"tagName":"p"},{"type":"text","content":"Presentation selected for DDW ‘Poster of Distinction’ recognition","length":65,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced new preclinical data supporting the design and potential of SER-603, a next-generation cultivated live biotherapeutic candidate for inflammatory bowel disease (IBD), being presented at Digestive Disease Week (DDW) 2026, taking place May 2–5, 2026, in Chicago, IL. The poster, titled “The Rational Design of SER-603: A Next Generation Cultivated Microbial Consortia to Treat IBD,” which has been selected as a DDW ‘Poster of Distinction,’ highlights Seres’ integrated approach to the design of microbiome therapeutics, combining rational strain selection and a novel biomarker-driven patient stratification.","length":777,"tagName":"p"},{"type":"text","content":"“We are advancing next-generation live biotherapeutics through a rational, data-driven design strategy to address underlying drivers of IBD that current therapeutics do not,” said Matthew Henn, Ph.D., President and Chief Scientific Officer of Seres. “SER-603 is designed to enable more precise modulation of inflammatory pathways relevant to IBD by combining the targeting of microbial functions linked to epithelial barrier integrity and mucosal healing with a biomarker-based approach to patient stratification. By leveraging insights from clinical datasets and tr...